Physician profile
Danielle L Doerr
NPI 1487940649
$4,239.78
in general payments reported to CMS, 2019-2025
33 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $431 · 2023: $1,165 · 2024: $1,332 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.22 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $581.74 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $555.70 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $439.42 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $383.08 | 2022-2025 | |
| Amgen INC. | $261.11 | 2023-2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $117.09 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $116.17 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $99.72 | 2024-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.30 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $85.26 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $70.07 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.38 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $63.36 | 2025 | |
| Axsome Therapeutics, INC. | $57.30 | 2023-2024 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.27 | 2022-2025 | |
| Tris Pharma INC | $52.83 | 2024-2025 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $51.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.47 | 2022-2024 | |
| Astellas Pharma US INC | $38.30 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.36 | 2023-2025 | Jardiance |
| Abbott Laboratories | $30.58 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $30.44 | 2022-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $22.67 | 2023 | Azstarys |
| Exact Sciences Corporation | $19.59 | 2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $18.91 | 2024 | Unithroid |
| Phathom Pharmaceuticals, INC. | $15.25 | 2024 | Voquezna |
| Globus Medical, INC. | $15.01 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $14.22 | 2022 | |
| Currax Pharmaceuticals LLC | $14.16 | 2023 | Contrave |
| Kowa Pharmaceuticals America, INC. | $14.14 | 2023 | Livalo |
| Nevro Corp. | $13.70 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Doerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.